Skip to main content

EX9536-4388 SELECT: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

NCT03574597

SELECT: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Associated Conditions

Obesity-Drug Study

Principal Investigator

Sponsor

Novo Nordisk

Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. A completed study showed that semaglutide reduced the risk of cardiovascular events (e.g. heart attack and stroke) in patients with type 2 diabetes. In this study, we will check to see if semaglutide may reduce the risk of having cardiovascular events. We invite participants who have had a prior cardiovascular disease, and have overweight or obesity. The term “cardiovascular disease” refers to several conditions that affect your heart and blood vessels. These conditions include myocardial infarction (also known as a “heart attack”), a stroke (also known as a “brain attack”) and peripheral arterial disease ('also known as poor circulation'). Overweight and obesity is when your body stores too much body fat compared to your height. People living with overweight or obesity are more likely to have cardiovascular events and experience other health conditions. This study will look mainly at the effect of semaglutide on cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.'

This study is currently enrolling.


Interested in Participating?

Please call (407) 303-7193 or fill out the Contact Form below for more information.